Information Provided By:
Fly News Breaks for October 6, 2015
ATRC
Oct 6, 2015 | 07:57 EDT
Canaccord sees the weakness in AtriCure following its acquisition announcement as a buying opportunity, as the firm believes the acquisition of nContact will strengthen the company's presence in the AF market, expand its ability to penetrate the large stand-alone AF opportunity and drive a higher long-term growth rate. Canaccord lowered its price target to $28 from $31 on AtriCure shares but reiterated its Buy rating on the stock.
News For ATRC From the Last 2 Days
ATRC
ATRC
Apr 23, 2024 | 06:16 EDT
Oppenheimer analyst Suraj Kalia upgraded AtriCure to Outperform from Perform with a $32 price target.
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.